Integrated noninvasive diagnostics for prediction of survival in immunotherapy [0.03%]
免疫治疗生存预测的集成无创诊断方法
M Yeghaian,Z Bodalal,T M Tareco Bucho et al.
M Yeghaian et al.
Background: Integrating complementary diagnostic data sources promises enhanced robustness in the predictive performance of artificial intelligence (AI) models, a crucial requirement for future clinical validation/impleme...
I Olivera,I Etxeberria,C Luri-Rey et al.
I Olivera et al.
Adoptive T-cell therapies (ACTs) including tumor-infiltrating lymphocytes and engineered T cells (transgenic T-cell receptor and chimeric antigen receptor T cells), have made an important impact in the field of cancer treatment over the pas...
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma [0.03%]
肿瘤浸润淋巴细胞与晚期黑色素瘤患者的免疫相关不良事件的关系研究
I A J van Duin,M Schuiveling,L S Ter Maat et al.
I A J van Duin et al.
Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggest...
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study [0.03%]
糖皮质激素对免疫治疗的黑色素瘤患者出现免疫相关不良事件的影响及生物标志物研究回顾性分析
F Costa Svedman,M Liapi,A Månsson-Broberg et al.
F Costa Svedman et al.
Background: Immune-related adverse events (IRAEs) during therapy with immune checkpoint inhibitors (ICIs) are common, and their management sometimes requires glucocorticoids (GCs). Predictors for development of IRAEs and ...
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial [0.03%]
一项I期临床试验：肾细胞癌序贯靶向免疫单药治疗的生物标志物评估(TRIBE试验)
K S Shohdy,M Pillai,K S Abbas et al.
K S Shohdy et al.
Background: Predictive biomarkers for immune checkpoint blockade in the second-line treatment of metastatic renal cell carcinoma (mRCC) are lacking. Mater...
Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering [0.03%]
生物材料介导的免疫细胞表面受体连接用于免疫工程
H Cui,L Zhang,Y Shi
H Cui
A wide variety of cell surface receptors found on immune cells are essential to the body's immunological defense mechanisms. Cell surface receptors enable immune cells to sense extracellular stimuli and identify pathogens, transmitting acti...
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities [0.03%]
免疫相关性肠炎、肝炎和心血管毒性的发病机制及管理进展
J McKenzie,E Sneath,A Trinh et al.
J McKenzie et al.
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant cha...
Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis [0.03%]
通过全转录组分析揭示透明细胞肾细胞癌中不同的空间景观
J I López,M F Hogan,B Sutton et al.
J I López et al.
Background: Clear-cell renal cell carcinoma (ccRCC) is the most common and aggressive form of renal cancer and a paradigm of inter- and intratumor heterogeneity. We carried out an exploratory digital spatial profiling of ...
Engineering approaches for innate immune-mediated tumor microenvironment remodeling [0.03%]
用于改造先天免疫介导的肿瘤微环境的工程方法
G I Kane,C F Lusi,M L Brassil et al.
G I Kane et al.
Cancer immunotherapy offers transformative promise particularly for the treatment of lethal cancers, since a correctly trained immune system can comprehensively orchestrate tumor clearance with no need for continued therapeutic intervention...
Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit [0.03%]
学术医药中先进治疗药物研发的基础及GMP模拟单元的作用
I Johanna,A Daudeij,F Devina et al.
I Johanna et al.
Following successes of authorized chimeric antigen receptor T-cell products being commercially marketed in the United States and European Union, product development of T-cell-based cancer immunotherapy consisting of cell-based advanced ther...